Cullinan Therapeutics, Inc. filings document formal disclosures for a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Recent Form 8-K reports furnish operating results and financial-condition updates, Regulation FD materials, and clinical disclosures tied to programs including CLN-978, CLN-049 and zipalertinib.
The filing record also covers corporate and governance matters, including definitive proxy disclosures on executive and director compensation, equity awards and shareholder voting matters. Material-event filings document portfolio and contractual actions, including the termination of an exclusive patent license related to CLN-617 through Cullinan Amber Corp.
Cullinan Therapeutics, Inc. President and CEO Nadim Ahmed reported an open-market sale of common stock. On February 20, 2026, he sold 16,381 shares at an average price of $13.62 per share, according to the Form 4 filing.
A footnote explains the sale was made to cover personal income tax obligations arising from the vesting of restricted stock units. After this transaction, Ahmed still holds 404,318 shares of Cullinan Therapeutics common stock directly.
Cullinan Therapeutics Chief Financial Officer Mary Kay Fenton reported a tax-related share sale. On this Form 4, she sold 4,398 shares of common stock at $13.62 per share in an open-market transaction. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, she directly owned 126,380 shares of Cullinan Therapeutics common stock.
CGEM filing shows a proposed resale of 1,752 shares of common stock through Morgan Stanley Smith Barney LLC.
The filing lists multiple recent 10b5-1 sales by Jennifer Michaelson, including 8,000 shares sold on 02/20/2026 for $114,400.00 and 4,000 shares sold on 01/22/2026 for $49,200.00.
Jennifer Michaelson proposes sale of 8,000 common shares. The filing lists 8,000 shares to be sold on 02/20/2026 via an exercise of stock options with cash consideration. The record also lists prior 10b5-1 sales totaling multiple transactions in 2025–2026.
Cullinan Therapeutics, Inc. reported that Chief Legal Officer Jacquelyn L. Sumer received a grant of a stock option covering 230,000 shares of common stock. This option was reported as an acquisition of a derivative security.
According to the disclosure, the shares underlying the option vest over four years, with one forty-eighth of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Following this grant, Sumer was reported as directly holding options on 230,000 shares.
Jones Jeffrey Alan reported acquisition or exercise transactions in this Form 4 filing.
Cullinan Therapeutics reported that its Chief Medical Officer, Jeffrey Alan Jones, received a grant of stock options covering 300,000 shares of common stock on February 18, 2026. These options vest over four years, with one-forty-eighth of the grant vesting in equal monthly installments until the fourth anniversary of the grant date.
Cullinan Therapeutics reported that President and CEO Nadim Ahmed was granted a stock option covering 828,000 shares of common stock. The option was awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
According to the disclosure, the shares underlying the option vest over four years, with one forty-eighth of the option shares vesting in equal monthly installments until the fourth anniversary of the grant date. After this grant, the CEO held options covering 828,000 shares directly.
Cullinan Therapeutics, Inc. reported that Chief Business Officer Corrine Savill received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $0.00 per share and vest over four years in equal monthly installments of one forty-eighth of the grant.
Cullinan Therapeutics, Inc. reported that its Chief Financial Officer, Mary Kay Fenton, acquired new equity awards. She received a stock option for 137,500 shares of common stock and a separate award covering 68,750 shares of common stock. The shares underlying the restricted stock unit award vest annually over four years. The shares underlying the option vest over four years, with one forty-eighth of the optioned shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Cullinan Therapeutics, Inc. reported that its Chief Scientific Officer, Jennifer Michaelson, received new equity awards. She was granted stock options for 115,000 shares at an exercise price of $0.0000 per share and 57,500 shares of common stock as an equity award.
According to the disclosure, the 57,500 common shares are in the form of restricted stock units that vest annually over four years. The 115,000 stock options vest over four years as well, with one forty-eighth of the options vesting in equal monthly installments until the fourth anniversary of the grant date.